1277 related articles for article (PubMed ID: 22945416)
1. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH
JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416
[TBL] [Abstract][Full Text] [Related]
2. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.
Bekhbat M; Chu K; Le NA; Woolwine BJ; Haroon E; Miller AH; Felger JC
Psychoneuroendocrinology; 2018 Dec; 98():222-229. PubMed ID: 30249443
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.
Weinberger JF; Raison CL; Rye DB; Montague AR; Woolwine BJ; Felger JC; Haroon E; Miller AH
Brain Behav Immun; 2015 Jul; 47():193-200. PubMed ID: 25529904
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
Mehta D; Raison CL; Woolwine BJ; Haroon E; Binder EB; Miller AH; Felger JC
Brain Behav Immun; 2013 Jul; 31():205-15. PubMed ID: 23624296
[TBL] [Abstract][Full Text] [Related]
6. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
7. Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT).
Webers C; Stolwijk C; Schiepers O; Schoonbrood T; van Tubergen A; Landewé R; van der Heijde D; Boonen A
Arthritis Res Ther; 2020 Sep; 22(1):225. PubMed ID: 32993799
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression.
Lee Y; Mansur RB; Brietzke E; Carmona NE; Subramaniapillai M; Pan Z; Shekotikhina M; Rosenblat JD; Suppes T; Cosgrove VE; Kramer NE; McIntyre RS
Brain Behav Immun; 2020 Aug; 88():631-639. PubMed ID: 32380271
[TBL] [Abstract][Full Text] [Related]
9. Effects of adjunctive N-acetylcysteine on depressive symptoms: Modulation by baseline high-sensitivity C-reactive protein.
Porcu M; Urbano MR; Verri WA; Barbosa DS; Baracat M; Vargas HO; Machado RCBR; Pescim RR; Nunes SOV
Psychiatry Res; 2018 May; 263():268-274. PubMed ID: 29605103
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
11. Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial.
Bergfeld IO; Mantione M; Hoogendoorn ML; Ruhé HG; Notten P; van Laarhoven J; Visser I; Figee M; de Kwaasteniet BP; Horst F; Schene AH; van den Munckhof P; Beute G; Schuurman R; Denys D
JAMA Psychiatry; 2016 May; 73(5):456-64. PubMed ID: 27049915
[TBL] [Abstract][Full Text] [Related]
12. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.
Nettis MA; Lombardo G; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Sforzini L; Bogdanova A; Cleare A; Young AH; Pariante CM; Mondelli V
Neuropsychopharmacology; 2021 Apr; 46(5):939-948. PubMed ID: 33504955
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
[TBL] [Abstract][Full Text] [Related]
15. Report of a preliminary discontinued double-blind, randomized, placebo-controlled trial of the anti-TNF-α chimeric monoclonal antibody infliximab in complex regional pain syndrome.
Dirckx M; Groeneweg G; Wesseldijk F; Stronks DL; Huygen FJ
Pain Pract; 2013 Nov; 13(8):633-40. PubMed ID: 23692303
[TBL] [Abstract][Full Text] [Related]
16. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.
Rapaport MH; Nierenberg AA; Schettler PJ; Kinkead B; Cardoos A; Walker R; Mischoulon D
Mol Psychiatry; 2016 Jan; 21(1):71-9. PubMed ID: 25802980
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
18. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
19. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
[TBL] [Abstract][Full Text] [Related]
20. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.
Papakostas GI; Shelton RC; Zajecka JM; Bottiglieri T; Roffman J; Cassiello C; Stahl SM; Fava M
J Clin Psychiatry; 2014 Aug; 75(8):855-63. PubMed ID: 24813065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
